Original scientific paper

https://doi.org/10.46419/vs.53.2.4

CRISPR/Cas9 and cancer

Nora Mimoune orcid.org/0000-0002-0900-3908 ; National high school of veterinary medicine, Algiers, Bab-Ezzouar, Algeria, Institute of veterinary sciences, LBRA Laboratory, University of Blida 1, Algeria
Mohamed Wail Bahouh ; National high school of veterinary medicine, Algiers, Bab-Ezzouar, Algeria
Said Boukhechem ; National Veterinary Institute, El-Khroub, Constantine, Algeria
Djamel Khelef ; National high school of veterinary medicine, Algiers, Bab-Ezzouar, Algeria
Rachid Kaidi ; Institute of veterinary sciences, LBRA Laboratory, university of Blida 1, Algeria
Ratiba Baazizi ; National High School of veterinary medicine, Bab Ezzouar, Algiers, Algeria

Abstract

CRISPR/Cas9 has become a powerful method for making changes to the genome of many organisms. First discovered in bacteria as part of an adaptive immune system, CRISPR/Cas9 and modified versions have found widespread use in genome engineering and in the activation or repression of gen expression. As such, CRISPR/Cas9 promises to accelerate cancer research by providing an efficient technology to dissect mechanisms of tumorigenesis, identify targets for drug development, and possibly arm cells for cell-based therapies. Here, we review the current applications of the CRISPR/Cas9 technology for cancer research and therapy. We highlight the impact of CRISPR/Cas9 in generating organoid and mouse models of cancer. Finally, we provide an overview of the first clinical trials applying CRISPR/Cas9 as a therapeutic approach against cancer.

Keywords

CRISPR/Cas9; cancer; trial; application

Hrčak ID:

259363

URI

https://hrcak.srce.hr/259363

Publication date:

24.6.2021.

Article data in other languages: croatian

Visits: 1.801 *